All In Biotech

NDA 215515 · Alnylam Pharms INC

Amvuttra

Vutrisiran Sodium · Subcutaneous

NovelOrphan

CDER novel approval, Jun 13, 2022: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jun 13, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

5

4 Phase 3, 1 recruiting

FAERS reports

2,969

2,505 serious, 745 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 6, 2025.

AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) 1.1 Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. 1.2 Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

Mechanism: Vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

Therapeutic areas: Neurology · Rare and genetic disease · Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 20, 2025 Supplement 6 · Efficacy · priority review OrphanLetterLabelReview
  • Jun 13, 2022 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
  • AMVUTTRA · VUTRISIRAN SODIUM EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vutrisiran" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death601
  • hospitalisation367
  • intentional dose omission262
  • product dose omission issue168
  • fall142
  • fatigue122
  • dyspnoea104
  • cardiac failure94
  • therapy interrupted94
  • gait disturbance87
  • arthralgia80
  • asthenia80

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
20211
202221
2023367
2024516
2025868
20261,195

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Amvuttra (Vutrisiran Sodium)

2024 spending

$141M

Beneficiaries

409

1,192 claims

Per beneficiary

$344,559

$236,450.75 per unit

View as table
YearSpending
2020$0
2021$0
2022$11,434,838
2023$67,368,549
2024$140,924,647

Part B: Amvuttra (Vutrisiran Sodium) · HCPCS J0225

2024 spending

$229M

Beneficiaries

603

3,103 claims

Per beneficiary

$379,824

2024 ASP limit $4,935.18 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$167,422,647
2024$229,033,879

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 30 on PubMed

Sponsor: Alnylam Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.